Tempest Therapeutics (NASDAQ:TPST) Posts Earnings Results, Misses Expectations By $2.25 EPS

Tempest Therapeutics (NASDAQ:TPST) announced its earnings results on Friday. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25), FiscalAI reports.

Tempest Therapeutics Stock Performance

NASDAQ TPST opened at $1.83 on Friday. The stock has a fifty day moving average of $1.94 and a 200-day moving average of $3.35. Tempest Therapeutics has a 52 week low of $1.50 and a 52 week high of $12.23. The stock has a market capitalization of $26.24 million, a P/E ratio of -0.30 and a beta of -1.75.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TPST. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. Wall Street Zen cut Tempest Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

Insider Transactions at Tempest Therapeutics

In other Tempest Therapeutics news, CEO Matthew Angel bought 231,482 shares of the business’s stock in a transaction that occurred on Tuesday, March 24th. The shares were acquired at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the transaction, the chief executive officer directly owned 231,482 shares in the company, valued at approximately $500,001.12. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.28% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. raised its position in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 162,560 shares of the company’s stock after purchasing an additional 27,952 shares during the period. Vanguard Group Inc. owned 3.66% of Tempest Therapeutics worth $1,671,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.